J Cancer 2019; 10(2):408-415. doi:10.7150/jca.28409 This issue

Research Paper

Elevated Serum S100A9 Indicated Poor Prognosis in Hepatocellular Carcinoma after Curative Resection

Jun Meng1*, Feng Gu2*, Hua Fang2, Bin Qu1✉

1. Department of Clinical Laboratory, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Rui Jin Er Road, Shanghai 200025, P.R. China
2. Department of Clinical Laboratory, People's Hospital of Shanghai Pudong District, No. 490, Chuan Huan Road South, Chuansha Town, Shanghai 201200, P.R. China
* These authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Meng J, Gu F, Fang H, Qu B. Elevated Serum S100A9 Indicated Poor Prognosis in Hepatocellular Carcinoma after Curative Resection. J Cancer 2019; 10(2):408-415. doi:10.7150/jca.28409. Available from https://www.jcancer.org/v10p0408.htm

File import instruction


Background: Previous studies suggest S100A9 is a promising biomarker for prognosis in cancer, including hepatocellular carcinoma (HCC). We examined the utility of serum S100A9 in predicting prognosis in HCC after curative resection.

Methods: We conducted a retrospective study of 379 HCC patients who underwent curative resection. Patients were randomly stratified into two independent groups to evaluate the prognostic value of S100A9. S100A9 was determined by ELISA.

Results: Patients with advanced disease showed significantly higher S100A9 levels (all P < 0.050). Serum S100A9 was elevated in patients who developed recurrence and death in both training and validation cohorts (all P < 0.050). In the training cohort, patients with higher preoperative S100A9 had a significantly shorter time to recurrence (15.50 vs. 64.00 months, P < 0.001) and decreased overall survival (34.80 months vs. not reached, P < 0.001). Cox regression demonstrated S100A9 was an independent indicator for poor prognosis after resection (both P < 0.050). These results were confirmed by the independent validation cohort.

Conclusions: Serum S100A9 is associated with dismal outcomes in HCC patients and can serve as a novel prognostic indicator for HCC patients after resection. Determination of S100A9 might help tailor treatment strategy to improve HCC patient prognosis.

Keywords: hepatocellular carcinoma, serum biomarker, S100A9, prognosis, curative resection